UMASANKAR RAMADOSS MD NPI 1962499806

NPI Details

Umasankar Ramadoss, MD is a hematology and oncology internal medicine in Columbia, MO with 33 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Umasankar Ramadoss, MD NPI is 1962499806. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1705 E BROADWAY
SUITE 100
COLUMBIA, MO
ZIP 65201-852
Phone: (573) 874-7800
Fax: (573) 443-3627

The NPI 1962499806 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, levoleucovorin, not otherwise specified, 0.5 mg (HCPCS:J0641)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, bendamustine hcl (bendeka), 1 mg (HCPCS:J9034)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of chest with contrast (HCPCS:71260)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Unclassified drugs (HCPCS:J3490)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Ct scan of chest without contrast (HCPCS:71250)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, midazolam hydrochloride, per 1 mg (HCPCS:J2250)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Drawing of blood for a medical problem (HCPCS:99195)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Continuing radiation therapy consultation per week (HCPCS:77336)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)

The enumeration date for this NPI number is 10/5/2005 and was last updated on 2/17/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.